Umeclidinium bromide 62.5mcg

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

CompletedNCT01772147

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2013-01-31End: 2013-08-31Updated: 2017-03-23

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

CompletedNCT01772134

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2013-01-01End: 2013-07-22Updated: 2018-01-29

Related Papers

Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.

2019-06-291 citations

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Therapy: An Integrated Post Hoc Analysis.

2018-09-0612 citations

Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo-Controlled Trials

Pulmonary Therapy2016-02-2219 citations

Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β<sub>2</sub>-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients

2015-09-013 citations